|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
109,470,000 |
Market
Cap: |
62.66(M) |
Last
Volume: |
627,989 |
Avg
Vol: |
626,290 |
52
Week Range: |
$0.5601 - $1.41 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Vaxart is a clinical-stage biotechnology company primarily focused on the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology proprietary oral vaccine platform. Co.'s oral vaccines are designed to generate immune responses that protect against a range of infectious diseases and may be useful for the treatment of chronic viral infections and cancer. Co.'s investigational vaccines are administered using a room temperature-stable tablet, rather than by injection. In addition, Co. is in early development of its first therapeutic vaccine targeting cervical cancer and dysplasia caused by human papillomavirus.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
25,000 |
Total Buy Value |
$0 |
$0 |
$0 |
$31,240 |
Total People Bought |
0 |
0 |
0 |
2 |
Total Buy Transactions |
0 |
0 |
0 |
2 |
Total Shares Sold |
0 |
0 |
0 |
0 |
Total Sell Value |
$0 |
$0 |
$0 |
$0 |
Total People Sold |
0 |
0 |
0 |
0 |
Total Sell Transactions |
0 |
0 |
0 |
0 |
End Date |
2024-03-17 |
2023-12-15 |
2023-06-16 |
2022-06-16 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Echerd Margaret |
SVP, Principal Accntng Officer |
|
2021-09-10 |
4 |
OE |
$0.77 |
$2,856 |
D/D |
1,801 |
1,801 |
|
- |
|
Tucker Sean |
SVP, Chief Scientific Officer |
|
2021-08-10 |
4 |
AS |
$10.20 |
$59,446 |
I/I |
(5,828) |
51,465 |
|
-22% |
|
Tucker Sean |
SVP, Chief Scientific Officer |
|
2021-08-10 |
4 |
AS |
$10.20 |
$42,554 |
D/D |
(4,172) |
43,881 |
|
-22% |
|
Echerd Margaret |
SVP, Principal Accntng Officer |
|
2021-08-10 |
4 |
AS |
$10.00 |
$18,010 |
D/D |
(1,801) |
0 |
|
-22% |
|
Echerd Margaret |
SVP, Principal Accntng Officer |
|
2021-08-10 |
4 |
OE |
$0.77 |
$2,852 |
D/D |
1,801 |
1,801 |
|
- |
|
Echerd Margaret |
SVP, Principal Accntng Officer |
|
2021-07-19 |
4 |
AS |
$8.00 |
$14,400 |
D/D |
(1,800) |
0 |
|
-13% |
|
Echerd Margaret |
SVP, Principal Accntng Officer |
|
2021-07-19 |
4 |
OE |
$0.77 |
$2,851 |
D/D |
1,800 |
1,800 |
|
- |
|
Finney Michael J. |
Director |
|
2021-06-18 |
4 |
OE |
$1.10 |
$200,000 |
D/D |
181,818 |
656,090 |
|
- |
|
Finney Michael J. |
Director |
|
2021-06-18 |
4 |
OE |
$0.68 |
$14,756 |
D/D |
21,700 |
474,272 |
|
- |
|
Yedid Robert A. |
Director |
|
2021-06-11 |
4 |
S |
$8.61 |
$86,109 |
D/D |
(10,000) |
8,240 |
|
19% |
|
Yedid Robert A. |
Director |
|
2021-06-11 |
4 |
OE |
$0.31 |
$5,654 |
D/D |
18,240 |
18,240 |
|
- |
|
Echerd Margaret |
SVP, Principal Accntng Officer |
|
2021-06-11 |
4 |
AS |
$8.00 |
$14,416 |
D/D |
(1,802) |
0 |
|
-19% |
|
Echerd Margaret |
SVP, Principal Accntng Officer |
|
2021-06-11 |
4 |
OE |
$0.77 |
$2,857 |
D/D |
1,802 |
1,802 |
|
- |
|
Echerd Margaret |
SVP, Principal Accntng Officer |
|
2021-06-09 |
4 |
AS |
$8.00 |
$380,440 |
D/D |
(47,555) |
0 |
|
-9% |
|
Echerd Margaret |
SVP, Principal Accntng Officer |
|
2021-06-09 |
4 |
OE |
$0.77 |
$90,883 |
D/D |
47,555 |
47,555 |
|
- |
|
Latour Wouter |
Director |
|
2021-05-07 |
4 |
S |
$7.13 |
$712,750 |
D/D |
(100,000) |
0 |
|
-14% |
|
Latour Wouter |
Director |
|
2021-05-07 |
4 |
OE |
$1.70 |
$170,000 |
D/D |
100,000 |
100,000 |
|
- |
|
Latour Wouter |
Director |
|
2021-05-06 |
4 |
S |
$6.54 |
$653,890 |
D/D |
(100,000) |
0 |
|
-18% |
|
Latour Wouter |
Director |
|
2021-05-06 |
4 |
OE |
$1.70 |
$170,000 |
D/D |
100,000 |
100,000 |
|
- |
|
Tucker Sean |
Chief Scientific Officer |
|
2021-03-16 |
4 |
OE |
$6.49 |
$6,529 |
D/D |
1,006 |
48,053 |
|
- |
|
Latour Wouter |
Director |
|
2021-03-04 |
4 |
S |
$6.04 |
$906,450 |
D/D |
(150,000) |
0 |
|
-13% |
|
Latour Wouter |
Director |
|
2021-03-04 |
4 |
OE |
$0.77 |
$115,500 |
D/D |
150,000 |
150,000 |
|
- |
|
Latour Wouter |
Director |
|
2020-11-23 |
4 |
S |
$6.32 |
$2,108,138 |
D/D |
(333,334) |
0 |
|
19% |
|
Tucker Sean |
Chief Scientific Officer |
|
2020-08-13 |
4 |
OE |
$6.49 |
$26,129 |
D/D |
4,026 |
51,679 |
|
- |
|
Latour Wouter |
Director |
|
2020-08-12 |
4 |
OE |
$0.30 |
$50,000 |
D/D |
166,667 |
333,334 |
|
- |
|
187 Records found
|
|
Page 3 of 8 |
|
|